Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Prepaid Assets (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Prepaid Assets for 3 consecutive years, with $474000.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Prepaid Assets fell 28.83% year-over-year to $474000.0, compared with a TTM value of $474000.0 through Sep 2024, down 28.83%, and an annual FY2023 reading of $537000.0, down 61.34% over the prior year.
  • Prepaid Assets was $474000.0 for Q3 2024 at Oramed Pharmaceuticals, down from $533000.0 in the prior quarter.
  • Across five years, Prepaid Assets topped out at $2.0 million in Q1 2022 and bottomed at $474000.0 in Q3 2024.
  • Average Prepaid Assets over 3 years is $893181.8, with a median of $666000.0 recorded in 2023.
  • The sharpest move saw Prepaid Assets grew 6.9% in 2023, then tumbled 64.79% in 2024.
  • Year by year, Prepaid Assets stood at $1.4 million in 2022, then tumbled by 61.34% to $537000.0 in 2023, then dropped by 11.73% to $474000.0 in 2024.
  • Business Quant data shows Prepaid Assets for ORMP at $474000.0 in Q3 2024, $533000.0 in Q2 2024, and $501000.0 in Q1 2024.